However, for patients who have already reached a healthy weight, microdosing may help maintain results while potentially providing ongoing metabolic benefits with fewer side effects
High-BMI patients (40+): The difference between 20% and 26% weight loss translates to clinically significant differences in outcomes for conditions like sleep apnea, joint disease, and metabolic syndrome severity
Retatrutide is an investigational weight loss injection given once weekly
Recently, the administration stated that it would not put into place a proposed rule that would require coverage of these medications under Medicaid
Rarer-yet-serious GLP-1 risks While rarer than the above side effects, there are some serious issues that could arise if youre taking a GLP-1
Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes